NCR Atleos Announces Timing for Investor Update Call

ATLANTA--(BUSINESS WIRE)-- NCR Atleos Corporation (NYSE: NATL) (“Atleos”) will host a conference call on Tuesday, December 5, 2023 at 4:30 p.m. Eastern Time to provide an update following the Company’s split from NCR Corp. that was effective on October 16, 2023.

Participants should plan to access the call 15 minutes prior to the start time to ensure a smooth connection. Details are as follows:

The live conference call and related presentation materials will also be available at https://investor.ncratleos.com/news-events/events-presentations. The conference call will be archived and available at the same site shortly after the conference call is complete.

For any difficulties accessing the conference call, please contact Brendan Metrano from NCR Atleos at 646-771-5740.

About Atleos
Atleos (NYSE: NATL) is a leader in expanding financial access by shifting transactions to the self-service channel and enabling financial institutions and retailers to leverage its ATM network – the largest independently-owned network in the world. Through its digital-first technology and unmatched global services operation, Atleos optimizes the branch, improves operational efficiency and maximizes self-service availability. Atleos is headquartered in Atlanta, Georgia, with 20,000 employees globally.

Web site: https://www.ncratleos.com
X (Twitter): https://twitter.com/ncratleos
Facebook: https://www.facebook.com/Atleos.NCR/
LinkedIn: https://www.linkedin.com/company/ncratleos
YouTube: https://www.youtube.com/@ncratleos
Instagram: https://www.instagram.com/ncratleos/

View source version on businesswire.com: https://www.businesswire.com/news/home/20231130259287/en/

Investor Contact
Brendan Metrano
NCR Atleos
[email protected]

Media Contact
Scott Sykes
NCR Atleos
[email protected]

Source: NCR Atleos Corporation

You May Also Be Interested In

• German Crews Join Italy’s round‑the‑coast Marina Militare Nastro Rosa Tour 2026
• European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resect
• Canada Nickel Awards Exclusive Mandate for US$600 million Investment Tax Credit Loan Facility to SB1 Markets AS